Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Am J Obstet Gynecol. 2024 Feb 15;230(6):657.e1–657.e17. doi: 10.1016/j.ajog.2024.02.006

TABLE 3.

Logistic regression models of interest in over-the-counter progestin-only pill use among an online sample of transgender, nonbinary, and gender-expansive people assigned female or intersex at birth in the United States

Independent variable and adjustment set to control for confounding Interested in over-the-counter progestin-only pill usea
Odds ratio 95% confidence interval P value

Model 1: age (y) (n=1415), no adjustment was necessary to estimate the total effect of this variable on interest in over-the-counter progestin-only pill use

 18–24 1.67 1.33–2.10 <.001b

 25–34 (ref)

 35–44 0.85 0.60–1.21 .37

 45–49 0.49 0.22–1.11 .09

Model 2: education level (n=1381), adjusted for age and race and ethnicity

 High school degree or less 3.02 1.94–4.71 <.001b

 Some college, trade, or technical school 1.04 0.78–1.39 .77

 College degree (ref)

 Some graduate or professional study 1.12 0.73–1.73 .60

 Graduate or professional degree 0.70 0.51–0.96 .03b

Model 3: currently employed (n=1383), adjusted for education

 Yes 0.97 0.75–1.26 .84

 No (ref)

Model 4: currently a student (n=1396), adjusted for age

 Yes 1.26 0.98–1.61 .07

 No (ref)

Model 5: marital status (n=1387), adjusted for age and education

 Single, never married 1.02 0.75–1.39 .88

 Married, civil union, registered domestic partnership, or engaged (ref)

 Divorced, widowed, separated 1.23 0.71–2.13 .46

 Other 0.58 0.24–1.45 .25

Model 6: has health insurance (n=1,392), adjusted for employment, student status, and marital status

 Yes (ref)

 No or donť know 1.91 1.24–2.93 .003b

Model 7: considers self at risk for unintended pregnancy (n=1400), adjusted for age, marital status, and participant sterilization

 Yes 1.33 0.96–1.85 .08

 No or do not know (ref)

Model 8: current oral contraceptive use (n=1394), adjusted for marital status, participant sterilization, insurance status, and considering self at risk for future unplanned pregnancy

 Yes 1.69 1.17–2.44 .005b

 No or do not know (ref)

Model 9: ever progestin-only pill use (n=1413), adjusted for ever having been pregnant and wanting to avoid estrogen generally

 Yes 2.32 1.70–3.17 <.001b

 No or do not know (ref)

Model 10: is sterilized or has had tubes tied, ovaries removed, and/or uterus removed or other procedure that makes getting pregnant impossible (n=1385), adjusted for age, education, marital status, and ever having been pregnant

 Yes 0.31 0.12–0.79 .01b

 No (ref)

Model 11: ever use of testosterone for gender affirmation (n=1415), adjusted for age and wanting to avoid estrogen generally

 Yes 0.72 0.57–0.90 .004b

 No (ref)

Model 12: has ever used contraception for gender affirmation (n=1413), adjusted for age

 Yes 1.31 0.93–1.86 .13

 No or do not know (ref)

Model 13: Wants to avoid estrogen generally (n=1,415), adjusted for age and ever having used testosterone

 Yes 1.32 1.04–1.67 .02b

 No or do not know (ref)

Model 14: wants to avoid estrogen because they view it as a female or feminizing hormone (n=1413), adjusted for age and ever having used testosterone

 Yes 1.72 1.36–2.19 <.001b

 No or do not know (ref)

Model 15: ever felt that opinions about their gender identity and/or sexual orientation from healthcare staff have negatively impacted them in a healthcare setting (n=1305), adjusted for age, education, and region

 Yes 1.08 0.86–1.36 .50

 No or do not know (ref)

We used the directed acyclic graph approach16 to select covariates for each model. Supplemental Appendix B contains the directed acyclic graphs.

a

Participants were considered interested in over-the-counter progestin-only pill use if they reported “yes” (vs “no” or “don’t know”) to a question asking if they would use a birth control pill that only had progestin that they could buy over the counter (without a prescription)

b

Indicates P<.05 in logistic regression.

Grindlay. Transgender interest in over-the-counter progestin-only pills. Am J Obstet Gynecol 2024.